secondary amyloidosis

(redirected from AA amyloidosis)
Also found in: Dictionary, Thesaurus, Medical.
Related to AA amyloidosis: AL amyloidosis, reactive amyloidosis

secondary amyloidosis

[′sek·ən‚der·ē ‚am·ə‚lȯi′dō·səs]
(medicine)
Amyloidosis that usually follows chronic suppurative, inflammatory diseases, such as tuberculosis, osteomyelitis, and bronchiectasis.
Mentioned in ?
References in periodicals archive ?
Therefore, negative light chain staining in association with amyloid does not rule out AL amyloidosis and may not be suggestive of AA amyloidosis in renal biopsies.
A proposed histopathologic classification, scoring, and grading system for renal amyloidosis: standardization of renal amyloid biopsy report
Natural history and outcome in systemic AA amyloidosis.
Amyloidosis--where are we now and where are we heading?
Additional injuries that may be related to the underlying neoplasm or its treatment regimen include TMA, AA amyloidosis, MN, IgAN, MPGN, pauci-immune crescentic GN, FSGS, minimal-change disease, acute interstitial nephritis, and xanthogranulomatous pyelonephritis.
Nonneoplastic kidney diseases in adult tumor nephrectomy and nephroureterectomy specimens: common, harmful, yet underappreciated
Neurochem has also submitted for marketing approval eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis in the European Union and Switzerland.
Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
The Company also filed for marketing approval for eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis in Switzerland.
Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
Our treatment approach, up to this point, has been limited to controlling the inflammatory condition that underlies the development of AA amyloidosis.
Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA(TM)) Treatment for Patients with Amyloid A (AA) Amyloidosis
The data that emerged from the Phase II/III clinical trial is indicative of the product candidate's consistent benefit on slowing the decline in kidney function associated with AA amyloidosis.
At Annual General Meeting of Shareholders (AGM) - Neurochem provides update on core product candidates and recent financing of us$80 million
Kiacta has shown promising efficacy in the systemic inflammatory disease AA amyloidosis, and we are pleased to have the opportunity to assess it as a potential therapy for sarcoidosis, an orphan indication that has few current treatment options.
Transparency Life Sciences To Conduct Sarcoidosis Trial For Auven Therapeutics' Kiacta(TM) Using Crowdsourcing And Telemonitoring
Increasing fatal AA amyloidosis in hunting falcons and how to identify the risk: a report from the United Arab Emirates.
Serum amyloid A as an indicator of health status in falcons
Most of our AA amyloidosis cases were classified as classes II, III, and IV, in which glomerular amyloid deposits were more commonly associated with the arteriolar walls.
A proposed histopathologic classification, scoring, and grading system for renal amyloidosis
Colchicine treatment of AA amyloidosis of familial Mediterranean fever.
Chronic Familial Mediterranean Fever with development of secondary amyloidosis
KIACTA(TM) is being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis.
BELLUS HEALTH/CELTIC THERAPEUTICS DEVELOP KIACTA

Encyclopedia browser ?
Full browser ?